Tags

Type your tag names separated by a space and hit enter

Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients.
Chest 1994; 106(5):1414-8Chest

Abstract

We recently reported that inhaled acetaldehyde causes bronchoconstriction indirectly via histamine release in patients with asthma. The purpose of this study was to investigate a role of thromboxane A2 in acetaldehyde-induced bronchoconstriction in asthmatic airways. We investigated the bronchial response to inhalation of ascending doses (5, 10, 20, and 40 mg/ml) of acetaldehyde in nine asthmatic subjects who were treated with placebo or OKY-046, a selective thromboxane A2 synthetase inhibitor, of 200 mg twice a day for 3 days, and 200 mg on the fourth day (test day) in a double-blind, randomized, placebo-controlled, crossover fashion. Percentage decreases in FEV1 caused by 20 and 40 mg/ml of acetaldehyde inhalation were significantly (p < 0.05 and p < 0.01, respectively) prevented by the pretreatment with OKY-046. Geometric mean value (geometric standard error of the mean) of acetaldehyde concentration producing a 20 percent fall in FEV1 (PC20-Ac-CHO) was significantly (p < 0.01) greater with the OKY-046 pretreatment (72.2 [1.1] mg/ml) than with the placebo pretreatment (19.8 [1.2] mg/ml). We conclude that thromboxane A2 is one of contributors to acetaldehyde-induced bronchoconstriction in asthmatic subjects. It suggests that thromboxane A2 may play an important role in endogenous histamine-induced bronchoconstriction caused by acetaldehyde in asthmatic airways. We believe that this is a first report on the interaction between endogenous histamine and thromboxane A2 in asthmatic subjects.

Authors+Show Affiliations

Division of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7956393

Citation

Myou, S, et al. "Inhibitory Effect of a Selective Thromboxane Synthetase Inhibitor, OKY-046, On Acetaldehyde-induced Bronchoconstriction in Asthmatic Patients." Chest, vol. 106, no. 5, 1994, pp. 1414-8.
Myou S, Fujimura M, Nishi K, et al. Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients. Chest. 1994;106(5):1414-8.
Myou, S., Fujimura, M., Nishi, K., Ohka, T., & Masuda, T. (1994). Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients. Chest, 106(5), pp. 1414-8.
Myou S, et al. Inhibitory Effect of a Selective Thromboxane Synthetase Inhibitor, OKY-046, On Acetaldehyde-induced Bronchoconstriction in Asthmatic Patients. Chest. 1994;106(5):1414-8. PubMed PMID: 7956393.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients. AU - Myou,S, AU - Fujimura,M, AU - Nishi,K, AU - Ohka,T, AU - Masuda,T, PY - 1994/11/1/pubmed PY - 1994/11/1/medline PY - 1994/11/1/entrez SP - 1414 EP - 8 JF - Chest JO - Chest VL - 106 IS - 5 N2 - We recently reported that inhaled acetaldehyde causes bronchoconstriction indirectly via histamine release in patients with asthma. The purpose of this study was to investigate a role of thromboxane A2 in acetaldehyde-induced bronchoconstriction in asthmatic airways. We investigated the bronchial response to inhalation of ascending doses (5, 10, 20, and 40 mg/ml) of acetaldehyde in nine asthmatic subjects who were treated with placebo or OKY-046, a selective thromboxane A2 synthetase inhibitor, of 200 mg twice a day for 3 days, and 200 mg on the fourth day (test day) in a double-blind, randomized, placebo-controlled, crossover fashion. Percentage decreases in FEV1 caused by 20 and 40 mg/ml of acetaldehyde inhalation were significantly (p < 0.05 and p < 0.01, respectively) prevented by the pretreatment with OKY-046. Geometric mean value (geometric standard error of the mean) of acetaldehyde concentration producing a 20 percent fall in FEV1 (PC20-Ac-CHO) was significantly (p < 0.01) greater with the OKY-046 pretreatment (72.2 [1.1] mg/ml) than with the placebo pretreatment (19.8 [1.2] mg/ml). We conclude that thromboxane A2 is one of contributors to acetaldehyde-induced bronchoconstriction in asthmatic subjects. It suggests that thromboxane A2 may play an important role in endogenous histamine-induced bronchoconstriction caused by acetaldehyde in asthmatic airways. We believe that this is a first report on the interaction between endogenous histamine and thromboxane A2 in asthmatic subjects. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/7956393/Inhibitory_effect_of_a_selective_thromboxane_synthetase_inhibitor_OKY_046_on_acetaldehyde_induced_bronchoconstriction_in_asthmatic_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(15)44332-6 DB - PRIME DP - Unbound Medicine ER -